Mynvax Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
34
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$5.63M
- Investors
-
15
Mynvax General Information
Description
Developer of novel drugs designed to be used in vaccines for respiratory viruses. The company's drugs specialize in the treatment of flu and infectious diseases for the healthcare industry, enabling medical professionals to improve their patients' recovery.
Contact Information
Website
www.mynvax.comCorporate Office
- Brigade MLR Centre, Number 50, 3rd Floor
- Vani Vilas Road, Basavanagudi
- Bangalore, Karnataka 560004
- India
Corporate Office
- Brigade MLR Centre, Number 50, 3rd Floor
- Vani Vilas Road, Basavanagudi
- Bangalore, Karnataka 560004
- India
Mynvax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series A) | 24-May-2024 | $5.63M | Completed | Clinical Trials - Phase 2 | ||
| 6. Early Stage VC (Series A) | 19-Jul-2021 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC | 08-Jul-2020 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC | 30-Oct-2019 | Completed | Startup | |||
| 3. Equity Crowdfunding | Completed | Startup | ||||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Mynvax Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 CCPS | ||||||||
| Ordinary Shares | ||||||||
| Preferance Shares | ||||||||
| Ordinary Shares | ||||||||
| Ordinary Shares | 14,350 | $0.119892 | $117.54 | $117.54 | 1x | $117.54 | 24.33% | |
| Ordinary Shares | 667 | $0.119892 | $1.2 | $1.2 | 1x | $1.2 | 1.13% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Mynvax Comparisons
Industry
Financing
Details
Mynvax Competitors (5)
One of Mynvax’s 5 competitors is Premas Biotech, a Venture Capital-Backed company based in Gurugram, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Premas Biotech | Venture Capital-Backed | Gurugram, India | ||||
| Serum Institute of India | Private Equity-Backed | Pune, India | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| Bharat Biotech | Formerly PE-Backed | Hyderabad, India | ||||
| Moderna | Formerly VC-backed | Cambridge, MA |
Mynvax Patents
Mynvax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026083454-A1 | Disulphide-linked oligomerization domain, polypeptides, and uses thereof | Pending | 19-Oct-2024 | ||
| WO-2026069378-A1 | Hemagglutinin based immunogenic polypeptides, compositions and methods thereof | Pending | 26-Sep-2024 | ||
| WO-2024157279-A1 | Stabilized immunogens derived from spike of coronavirus, compositions and methods thereof | Inactive | 23-Jan-2023 | ||
| AU-2022425707-A1 | Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof | Pending | 31-Dec-2021 | ||
| EP-4456915-A1 | Polypeptide fragments, immunogenic composition against influenza virus, and implementations thereof | Pending | 31-Dec-2021 | A61K39/145 |
Mynvax Signals
Mynvax Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 1Funds Domestic Scheme 1 | Venture Capital | Minority | ||
| Accel India | Venture Capital | Minority | ||
| AL Trust (India) | Venture Capital | Minority | ||
| Equirus Capital | Investment Bank | Minority | ||
| Inviga (Bangalore) | PE/Buyout | Minority |
Mynvax FAQs
-
When was Mynvax founded?
Mynvax was founded in 2017.
-
Where is Mynvax headquartered?
Mynvax is headquartered in Bangalore, India.
-
What is the size of Mynvax?
Mynvax has 34 total employees.
-
What industry is Mynvax in?
Mynvax’s primary industry is Drug Discovery.
-
Is Mynvax a private or public company?
Mynvax is a Private company.
-
What is the current valuation of Mynvax?
The current valuation of Mynvax is .
-
What is Mynvax’s current revenue?
The current revenue for Mynvax is .
-
How much funding has Mynvax raised over time?
Mynvax has raised $12.6M.
-
Who are Mynvax’s investors?
1Funds Domestic Scheme 1, Accel India, AL Trust (India), Equirus Capital, and Inviga (Bangalore) are 5 of 15 investors who have invested in Mynvax.
-
Who are Mynvax’s competitors?
Premas Biotech, Serum Institute of India, BioNTech, Bharat Biotech, and Moderna are competitors of Mynvax.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process